NASD · Healthcare · Biotechnology · United Kingdom
Silence Therapeutics Plc ADR is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Silence Therapeutics is a biotechnology company that develops short interfering RNA molecules to inhibit expression of disease-associated genes. The company uses its mRNAi GOLD platform to target genes in the liver for rare diseases, cardiometabolic conditions, and obesity. Its product candidates work by harnessing the body's natural gene-silencing mechanism to reduce disease-associated protein production.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Silence Therapeutics Plc ADR stock.
Overvalued: intrinsic value $1.18 per share, market price $19.75, margin of safety -1572.5% (as of 2026-10-30).
A 2.4x revenue multiple, discounted for its losses, values the shares at $1.18; the price of $19.75 is 1573% above that value.
123 more in this industry show a wider margin of safety.
SLN is overvalued (as of the 2026-10-30 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $1.18; the price of $19.75 is 1573% above that value.
$1.18 per share (as of the 2026-10-30 close), against a market price of $19.75. That is a margin of safety of -1572.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.